老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Health Innovation Active ETF
33.56
0.0000
成交量：
69
成交額：
2,349.44
市值：
1,342.44萬
市盈率：
- -
高：
33.56
開：
33.56
低：
33.56
收：
33.56
52周最高：
34.86
52周最低：
25.79
股本：
40.00萬
流通股本：
40.00萬
量比：
0.16
換手率：
0.02%
股息：
0.08
股息率：
0.24%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
歐康維視生物-B(01477)：OT-211 III期臨床試驗完成患者入組
智通财经
·
09/02
海西新藥：已提交自研創新藥HX9428臨床試驗申請
财中社
·
09/02
諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率 安全性表現良好
智通财经
·
09/02
蘇州市委書記範波會見強生執行副總裁史明德一行
南方财经网
·
09/02
眾生藥業(002317.SZ)：昂拉地韋片新增適應症臨床試驗申請獲受理
智通财经
·
09/02
範波會見強生執行副總裁史明德一行，共同出席強生蘇州20周年活動
智通财经
·
09/02
國家藥監局正式啓動滴眼劑一致性評價工作
智通财经
·
09/02
單日暴漲177%的莫德納，對全球醫藥產業意味着什麼？
蓝鲸财经
·
09/02
澳大利亞批准金佰利·克拉克收購肯維尤，但要求其剝離「Carefree」和「Stayfree」品牌
路透中文
·
09/02
澳大利亞批准金佰利·克拉克收購肯維尤，但要求其剝離「Carefree」和「Stayfree」品牌
路透中文
·
09/02
世衞組織：爾韋博疫苗目前僅應在研究方案框架內用於本迪布焦病毒（BVDV）
美股速递
·
09/01
石藥集團(01093.HK)：SYH2056片用於治療抑鬱症的I期臨床試驗在中國正式啓動
智通财经
·
09/01
智飛生物(300122.SZ)：凍幹人用狂犬病疫苗(ZFB-3細胞)臨床試驗申請獲受理
智通财经
·
09/01
中關村(000931.SZ)下屬公司鹽酸哌甲酯緩釋咀嚼片獲批開展臨床試驗
智通财经
·
09/01
智飛生物：智飛龍科馬疫苗臨床試驗申請獲受理，60日內可開展
智通财经
·
09/01
中關村：北京華素40mg鹽酸哌甲酯緩釋咀嚼片獲准開展臨床試驗
智通财经
·
09/01
諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷
智通财经
·
09/01
默克集團股價上漲2.6%，此前滙豐銀行將其評級從持有上調至買入。
智通财经
·
09/01
吉倫泰研製的靶向整合素αvβ3治療核藥獲得國家藥監局臨床試驗批件
智通财经
·
09/01
美國醫療保險和醫療補助服務中心：將為阿肯色州農村醫院提供資金，用於升級救護車、拓展遠程醫療服務並安裝應急發電機
智通财经
·
09/01
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.5609,"timestamp":1789657525735,"preClose":33.5609,"halted":0,"volume":69,"delay":0,"changeRate":0,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-17 14:17:50 EDT","open":33.5609,"high":33.5609,"low":33.5609,"amount":2349.444687,"amplitude":0,"askPrice":34.18,"askSize":1000,"bidPrice":34.1,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002375,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.3654,"timestamp":1789589403907,"change":-0.1509,"changeRate":-0.004496,"amplitude":0},"volumeRatio":0.162049,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.162049,"shares":400000,"dividePrice":0.0797,"high":33.5609,"amplitude":0,"preClose":33.5609,"low":33.5609,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.5609,"eps":0,"divideRate":0.002375,"volume":69,"delay":0,"ttmEps":0,"open":33.5609,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":32.8027,"twentyDayClose":34.7939,"sixtyDayClose":28.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664811365","title":"歐康維視生物-B(01477)：OT-211 III期臨床試驗完成患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811365","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811365?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:14","pubTimestamp":1788351299,"startTime":"0","endTime":"0","summary":"欧康维视生物-B公布，OT-211在中华人民共和国开展的III期临床试验已于近日完成合共398名患者的入组。2026年3月，OT-211于中国的III期临床试验完成首例患者入组，标志着 OT-211在中国的临床开发取得重要里程碑进展，并体现了本集团致力于为DED患者推进创新疗法。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。本次OT-211的成功入组标志着公司与Alcon集团在新药开发领域也形成了强有力的合作与绑定，为后续新药共同探索与开发打下基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","MDTX","01477","IBBJ","BK1574","BMED","BK1191","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新藥：已提交自研創新藥HX9428臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819950?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBJ","BK1161","MDTX","MEDX","IBBQ","BK1191","LNGR","02637","06978","BK1574","BMED","159992","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815045","title":"諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率 安全性表現良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:11","pubTimestamp":1788347485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0208291251.USD","LU0211331839.USD","IBBQ","NVS","MEDX","PSYK","BMED","IE00BJT1NW94.SGD","BK4585","IBBJ","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4532","BK4578","IE0002141913.USD","LU0320765489.SGD","PPH","BK4588","IE00B2B36J28.USD","BK4007","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664816902","title":"蘇州市委書記範波會見強生執行副總裁史明德一行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664816902","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664816902?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:04","pubTimestamp":1788347047,"startTime":"0","endTime":"0","summary":"南方财经9月2日电，据苏州日报，9月2日，苏州市委书记范波会见了强生执行副总裁、医疗科技全球主席史明德一行，共同出席强生苏州20周年活动。强生公司是《财富》世界500强，是全球医疗健康行业头部企业，2006年落户苏州以来，不断增资扩产，推动强生苏州产业园发展成为强生医疗科技在华最大的供应链基地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862919472.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862919472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RXL","JNJ","PJP","IHE","GDOC","IE0034235303.USD","LU1032955483.USD","LU1043141396.HKD","LU0124676726.USD","LU1989771016.USD","BK4581","BK4504","IXJ","LU0320765646.SGD","LU2471134796.USD","LU0795875169.SGD","LU1228905037.USD","LU2505996681.GBP","BMED","LU1929549753.HKD","IE00B2B36J28.USD","JDOC","TRUH","FHLC","LU1674673428.USD","IE00BBT3K403.USD","BK4532","MEDX","LU1506573853.SGD","IYH","LU1066051498.USD","LU1894683348.USD","VHT","XLV","LU2129689605.HKD","LU1061106388.HKD","LU1043141123.HKD","LU1914381329.SGD","IE0000B7K699.USD","LU2505996509.AUD","LU1280957306.USD","LU2430703095.HKD","BK4585","FTXH","LU1066051811.HKD","LU2236285917.USD","LU0820561909.HKD","IE00BFTCPJ56.SGD","BK4588","LU2129689514.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818429","title":"眾生藥業(002317.SZ)：昂拉地韋片新增適應症臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818429","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818429?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:59","pubTimestamp":1788343190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新药物昂拉地韦片新增适应症“治疗高并发症风险甲型流感”的药物临床试验申请获得国家药品监督管理局(NMPA)受理，并收到《受理通知书》。据悉，昂拉地韦片是具有明确作用机制和全球自主知识产权的全球首款流感RNA聚合酶PB2蛋白抑制剂，已于2025年5月获NMPA批准上市。此次昂拉地韦片新增适应症拟开展III期临床研究入组12岁及以上青少年和成人甲型流感参与者，评估昂拉地韦片治疗甲型流感病毒感染且存在流感相关并发症高风险参与者的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002317","PSYK","MDTX","IBBJ","BK0239","BK0077","IBBQ","BK0188","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664652890","title":"範波會見強生執行副總裁史明德一行，共同出席強生蘇州20周年活動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664652890","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664652890?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:21","pubTimestamp":1788340918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4533","BK4581","GDOC","LU1066053197.SGD","LU2468319806.SGD","LU0320765646.SGD","LU0345769128.USD","PJP","LU2417539215.USD","LU2430703178.SGD","LU1732800096.USD","BK4504","IE00BZ1G4Q59.USD","LU1066051811.HKD","LU0122379950.USD","LU1121112475.USD","IE00BGHQF631.EUR","FTXH","LU1629891620.HKD","IE00B3T34201.USD","BK4568","FHLC","LU0289739699.SGD","LU0070217475.USD","TRUH","VHT","LU0234572021.USD","LU0792757196.USD","LU1718418525.SGD","IE00B42XCP33.USD","JNJ","LU1228905037.USD","LU2592432038.USD","IE000MB6IJN5.SGD","IHE","IE000WAW04H5.SGD","LU2750360997.AUD","BMED","LU2347655156.SGD","LU2129689431.USD","IYH","RXL","IE000M9KFDE8.USD","LU0964807845.USD","LU1221951046.USD","JDOC","MEDX","IXJ","XLV","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897083","title":"國家藥監局正式啓動滴眼劑一致性評價工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897083?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:13","pubTimestamp":1788340392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664589566","title":"單日暴漲177%的莫德納，對全球醫藥產業意味着什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664589566","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664589566?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 12:10","pubTimestamp":1788322216,"startTime":"0","endTime":"0","summary":"引发一切的，是当天莫德纳与默沙东联合公布的一份三期临床试验顶线结果。177%不是一天涨出来的要更进一步理解此次大涨，需要先理解市场之前对莫德纳的评判逻辑。默沙东为此等了十年，2016年签下合作协议并支付2亿美元首付款，2018年追加1.25亿美元战略投资，2022年正式行使共同开发选择权。8月20日下跌23.55%之后，莫德纳并没有跌回去。这里值得单独一提的是8月20日涨幅最大的云顶新耀，这","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788143888266092586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0859254822.USD","MRNX","LU0965509010.AUD","BK1574","LU1941712264.USD","BK4551","BK4139","LU0058720904.USD","LU1917777945.USD","LU1929549753.HKD","IE00B4R5TH58.HKD","LU0265550359.USD","LU1069347547.HKD","LU0124676726.USD","SG9999001440.SGD","LU2468319806.SGD","LU1066053197.SGD","LU0122379950.USD","LU2106854487.HKD","LU0320765646.SGD","LU0689626769.HKD","MRK","LU1061106388.HKD","IE000M9KFDE8.USD","LU0965509101.SGD","LU0266013472.USD","LU1989772923.USD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU0648001328.SGD","LU2361044865.SGD","LU1116320901.HKD","LU1037948897.HKD","SG9999014542.SGD","IE0009355771.USD","PAWZ","GNOM","LU1066051498.USD","LU1934455863.HKD","LU0203345920.USD","LU2360032135.SGD","SG9999014575.USD","LU0289739699.SGD","BK4548","BK4501","LU0203347892.USD","BK4550","01952","BK4516","SG9999001176.USD","BK1583","LU0432979614.USD","IHE","SG9999001176.SGD","XLV","LU2361045086.USD","LU0265550946.USD","LU1116320737.USD","BK4568","LU1291159041.SGD","LU2491050071.SGD","LU1162221912.USD","BK1161","IE00BLSP4239.USD","LU0208291251.USD","LU1941712348.USD","LU1699723380.USD","LU1989771016.USD","BK4007","LU2125154935.USD","LU2023250843.SGD","IE0002141913.USD","LU2357627491.SGD","LU1974910355.USD","LU1571399168.USD","LU2361044949.HKD","LU0098860793.USD","SGXZ57979304.SGD","LU2125909593.SGD","BK4585","LU1057294990.SGD","LU1923622614.USD","TRUH","SG9999015358.SGD","IE00BSNM7G36.USD","LU0234572021.USD","IE00BFTCPJ56.SGD","LU0861579265.USD","LGHT","LU2491050154.USD","SG9999002224.SGD","LU0965508806.USD","IDNA","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0006306889.USD","LU0823416689.USD","LU1037948541.HKD","LU2461242641.AUD","SG9999014559.SGD","VHT","BNTX","LU1066051225.USD","LU0985320562.USD","LU2023250504.SGD","LU1032466523.USD","IYH","BK4535","LU1035773651.USD","MRNA","LU2125909247.SGD","RXL","LU1989772840.SGD","LU1066051811.HKD","LU2433249047.HKD","PPH","HRTS","LU1023059063.AUD","BMED","FHLC","LU1934455194.USD","LU0868494708.USD","BK4533","JDOC","SG9999014567.USD","SG9999015341.SGD","FTXH","SG9999002232.USD","SG9999013999.USD","LU2125154778.USD","BK4559","GDOC","MRNY","LU0868494617.USD","LU0238689110.USD","LU0106261372.USD","LU0477156953.USD","LU0980610538.SGD","LU1201861249.SGD","LU2089984988.USD","LU1934455277.USD","WDNA","BK4588","IE00BJT1NW94.SGD","LU0320765489.SGD","LU1093756168.USD","BK4532","IE00B1BXHZ80.USD","LU2112291526.USD","LU0130102774.USD","IE00B2B36J28.USD","LU0211331839.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","BK4534","LU1585245621.USD","LU0942090050.USD","LU0130517989.USD","LU1093756325.SGD","IXJ","LU0070302665.USD","LU2324357040.USD","LU1983299246.USD","LU2491049909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664860837","title":"澳大利亞批准金佰利·克拉克收購肯維尤，但要求其剝離「Carefree」和「Stayfree」品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664860837","media":"路透中文","labels":["corporation","policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664860837?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:20","pubTimestamp":1788312053,"startTime":"0","endTime":"0","summary":"澳大利亚批准金佰利·克拉克收购肯维尤，但要求其剥离“Carefree”和“Stayfree”品牌路透9月2日-澳大利亚竞争监管机构周三批准了金佰利·克拉克KMB.O拟以400亿美元收购肯维尤KVUE.N的交易，但条件是该公司必须剥离肯维尤在澳大利亚的Carefree和Stayfree经期护理品牌，以消除竞争方面的担忧。据 上周报道，金佰利·克拉克还已向欧盟监管机构申请批准此次收购，欧盟委员会网站上的文件显示了这一情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4S44U042:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051811.HKD","IE00BLSP4239.USD","VHT","LU2236285917.USD","XLV","IHE","JDOC","LU2129689431.USD","IE00BBT3K403.USD","LU2471134796.USD","LU2505996509.AUD","IYH","KVUE","LU1778281490.HKD","LU2430703095.HKD","LU0882574055.USD","LU1894683348.USD","BK4183","IE0000B7K699.USD","LU0310800379.SGD","GLAM","IE00BVYPNV92.GBP","LU0234570918.USD","IE00BFTCPJ56.SGD","BMED","IE00BKVL7J92.USD","LU0795875169.SGD","IE00BLSP4452.SGD","FTXH","JNJ","LU1629891620.HKD","LU1267930573.SGD","FHLC","KMB","LU1674673691.USD","RXL","LU0820561909.HKD","IE0002141913.USD","BK4533","LU0124676726.USD","LU0889566641.SGD","RSPS","IXJ","MEDX","TRUH","LU0345770993.USD","SG9999001440.SGD","PJP","GDOC","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664860830","title":"澳大利亞批准金佰利·克拉克收購肯維尤，但要求其剝離「Carefree」和「Stayfree」品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664860830","media":"路透中文","labels":["corporation","policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664860830?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:20","pubTimestamp":1788312053,"startTime":"0","endTime":"0","summary":"澳大利亚批准金佰利·克拉克收购肯维尤，但要求其剥离“Carefree”和“Stayfree”品牌路透9月2日-澳大利亚竞争监管机构周三批准了金佰利·克拉克KMB.O拟以400亿美元收购肯维尤KVUE.N的交易，但条件是该公司必须剥离肯维尤在澳大利亚的Carefree和Stayfree经期护理品牌，以消除竞争方面的担忧。据 上周报导，金佰利·克拉克还已向欧盟监管机构申请批准此次收购，欧盟委员会网站上的文件显示了这一情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4T44U042:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU1267930573.SGD","BK4533","LU0310800379.SGD","TRUH","RXL","FHLC","LU2236285917.USD","MEDX","LU2129689431.USD","SG9999001440.SGD","BMED","LU0882574055.USD","VHT","XLV","LU1894683348.USD","IXJ","IE00BVYPNV92.GBP","IYH","IE0000B7K699.USD","LU0124676726.USD","LU1066051811.HKD","FTXH","LU2471134796.USD","IE00BBT3K403.USD","GLAM","LU0345770993.USD","LU1778281490.HKD","LU0820561909.HKD","BK4183","IE00BKVL7J92.USD","LU2430703095.HKD","IE0002141913.USD","LU1059921491.USD","RSPS","JDOC","JNJ","LU1629891620.HKD","IE00BFTCPJ56.SGD","GDOC","LU0234570918.USD","KMB","LU0889566641.SGD","LU0795875169.SGD","LU1674673691.USD","LU2505996509.AUD","IHE","IE00BLSP4452.SGD","PJP","KVUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181076454","title":"世衞組織：爾韋博疫苗目前僅應在研究方案框架內用於本迪布焦病毒（BVDV）","url":"https://stock-news.laohu8.com/highlight/detail?id=1181076454","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181076454?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276944,"startTime":"0","endTime":"0","summary":"世界卫生组织（WHO）表示，尔韦博（Ervebo）疫苗现阶段仅可在研究性方案框架下，用于针对本迪布焦病毒（Bundibugyo Virus, BVDV）的防控。这一表态凸显了该疫苗在当前阶段使用的严格限定条件——其应用范围被明确框定于科学研究的语境之内，而非广泛的常规接种。换言之，任何涉及此疫苗应对BVDV的举措，都必须依托于严谨的研究设计，以确保数据的完整性与安全性评估的可靠性。此间，专家亦强调，这种审慎态度反映出对新型疫苗在不同病毒株间交叉保护效力的未知性，以及循证决策的必要性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","LU0868494708.USD","LU1201861249.SGD","LU0965509101.SGD","LU1934455194.USD","LU1983299246.USD","LU1934455277.USD","LU2357627491.SGD","LU2360032135.SGD","LU0320765646.SGD","LU1066051225.USD","LU0861579265.USD","SG9999002232.USD","LU1093756325.SGD","SG9999014542.SGD","LU2361044865.SGD","IE00BBT3K403.USD","BK4516","LU2491049909.HKD","LU1989772923.USD","LU1699723380.USD","LU1057294990.SGD","LU1162221912.USD","LU1974910355.USD","LU0265550359.USD","LU1093756168.USD","IE0002141913.USD","LU1116320737.USD","LU1116320901.HKD","LU0985320562.USD","IE00BLSP4452.SGD","LU2089984988.USD","IE00B2B36J28.USD","LU0098860793.USD","LU2125909247.SGD","LU0058720904.USD","LU2125909593.SGD","LU1023059063.AUD","SG9999014559.SGD","PAWZ","BK4533","LU1037948541.HKD","IE00BFTCPJ56.SGD","BMED","LU0130102774.USD","LU1066053197.SGD","LU1585245621.USD","LU1066051498.USD","RXL","BK4588","SG9999015358.SGD","IE00BN8TJ469.HKD","LU2324357040.USD","LU1430594728.SGD","LU0266013472.USD","LU2361045086.USD","TRUH","LU0070302665.USD","GDOC","LU0106261372.USD","LU0203347892.USD","LU1061106388.HKD","LU0965508806.USD","LU0320765489.SGD","SG9999013999.USD","IE00BLSP4239.USD","VHT","LU1291159041.SGD","FTXH","LU2491050071.SGD","MRK","SG9999001176.SGD","IHE","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1032466523.USD","IYH","LU2023250504.SGD","LU0238689110.USD","IE000M9KFDE8.USD","BK4559","LU2125154935.USD","LU0124676726.USD","LU2106854487.HKD","LU1941712264.USD","LU1066051811.HKD","LU0203345920.USD","LU0208291251.USD","LU1571399168.USD","SGXZ57979304.SGD","SG9999002224.SGD","LU2461242641.AUD","BK4585","IXJ","SG9999014575.USD","HRTS","LU1989771016.USD","SG9999014567.USD","IE00B1BXHZ80.USD","XLV","LU0006306889.USD","LU0823416689.USD","LU2361044949.HKD","LU0211331839.USD","LU0965509010.AUD","IE0009355771.USD","FHLC","LU0859254822.USD","LU1989772840.SGD","LU1923622614.USD","LU0980610538.SGD","LU2468319806.SGD","LU0122379950.USD","LU0234572021.USD","LU0289739699.SGD","BK4534","LU0130517989.USD","LU1929549753.HKD","LU2023250843.SGD","SG9999001176.USD","LU0432979614.USD","LU1035773651.USD","LU0868494617.USD","LU0648001328.SGD","LU1917777945.USD","LU0265550946.USD","LU1037948897.HKD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU0689626769.HKD","LU1069347547.HKD","LU1934455863.HKD","LU2433249047.HKD","LU1941712348.USD","LU2112291526.USD","LU0965509283.SGD","SG9999001440.SGD","JDOC","LU0942090050.USD","IE00BSNM7G36.USD","BK4007","LU0477156953.USD","LU2491050154.USD","BK4550","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664355858","title":"石藥集團(01093.HK)：SYH2056片用於治療抑鬱症的I期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664355858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664355858?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 18:12","pubTimestamp":1788257547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","IBBQ","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832774","title":"智飛生物(300122.SZ)：凍幹人用狂犬病疫苗(ZFB-3細胞)臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664832774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:05","pubTimestamp":1788253557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的冻干人用狂犬病疫苗(ZFB-3细胞)获得国家药品监督管理局药物临床试验申请受理通知书。该药品用于预防狂犬病。通过接种该疫苗，可剌激机体产生抗狂犬病病毒的免疫力。该药品以公司自主研制的人二倍体细胞株(ZFB-3细胞)作为生产基质，与动物源性细胞狂犬病疫苗相比，理论上局部和全身不良反应发生率更小，且无致瘤性风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0239","LU1064130708.USD","BK0046","LU2580892789.USD","LU1064131003.USD","PSYK","LU1328615791.USD","LU2580892862.HKD","MDTX","BK0188","BMED","BK0196","IBBQ","LU2148510915.USD","300122","IBBJ","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083225","title":"中關村(000931.SZ)下屬公司鹽酸哌甲酯緩釋咀嚼片獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083225","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:59","pubTimestamp":1788253144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司北京华素制药股份有限公司(简称：北京华素)于近日收到国家药品监督管理局核准签发的盐酸哌甲酯缓释咀嚼片(规格：40mg)《药物临床试验批准通知书》。该药品拟开展用于注意缺陷多动障碍(ADHD)的临床试验。截至目前，中国境内仅1家原研进口获批上市，北京华素为国内第一家获批本品仿制药临床试验许可的企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0075","BK0239","000931","BK0028","BMED","IBBJ","BK0178","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083291","title":"智飛生物：智飛龍科馬疫苗臨床試驗申請獲受理，60日內可開展","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083291?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:53","pubTimestamp":1788252835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","BMED","PRTO","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664329148","title":"中關村：北京華素40mg鹽酸哌甲酯緩釋咀嚼片獲准開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2664329148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664329148?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 16:53","pubTimestamp":1788252832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831619","title":"諾華製藥(NVS.US)神經免疫管線「悲喜交加」：患者死亡致CAR-T臨床試驗暫停 MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831619","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831619?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:40","pubTimestamp":1788248407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药在神经与自身免疫领域迎来“冰火两重天”：公司因三名患者死亡紧急叫停八项CAR-T疗法临床试验;不过，其多发性硬化症口服药remibrutinib在后期临床试验中取得积极结果。CAR-T试验紧急暂停诺华制药在8月底暂停了八项针对自身免疫和神经系统疾病的实验性疗法临床试验，此前有三名患者死亡。诺华制药发言人表示，公司正在“对所观察到的安全事件进行全面审查”，并将这种致命免疫反应描述为CAR-T疗法中已知的安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0208291251.USD","IBBJ","IE0009355771.USD","BK1574","IE00B4R5TH58.HKD","LU0211331839.USD","NVS","MDTX","PPH","BK1191","01477","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0070302665.USD","IE00BJT1NW94.SGD","MEDX","IE00BFTCPJ56.SGD","BK4578","IBBQ","BK4007","LU0320765489.SGD","PSYK","BK4588","BK4585","BK4532","BMED","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664183676","title":"默克集團股價上漲2.6%，此前滙豐銀行將其評級從持有上調至買入。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664183676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664183676?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 15:04","pubTimestamp":1788246292,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IE0009355771.USD","LU1941712264.USD","LU1066051225.USD","LU0859254822.USD","BK4550","LU0238689110.USD","LU2125154935.USD","LU0868494617.USD","IE00B1BXHZ80.USD","LU2324357040.USD","LU2491050071.SGD","LU1989772923.USD","LU0965509101.SGD","LU0058720904.USD","LU2112291526.USD","LU2125909247.SGD","BK4516","IHE","LU2361045086.USD","LU1066051498.USD","LU1037948541.HKD","LU0985320562.USD","LU1201861249.SGD","LU1023059063.AUD","IYH","LU1116320901.HKD","LU0868494708.USD","LU0266013472.USD","IE00B2B36J28.USD","LU0980610538.SGD","IE00BSNM7G36.USD","LU0965509010.AUD","SG9999002232.USD","LU1934455863.HKD","BK4534","LU0130517989.USD","SG9999001440.SGD","LU1291159041.SGD","PPH","LU1929549753.HKD","LU1699723380.USD","LU1941712348.USD","IE00BLSP4239.USD","SG9999014567.USD","LU2125154778.USD","GDOC","LU1917777945.USD","SG9999002224.SGD","LU0203347892.USD","LU0477156953.USD","LU0106261372.USD","VHT","LU0689626769.HKD","LU1989771016.USD","LU2491050154.USD","LU0320765646.SGD","RXL","LU0432979614.USD","IXJ","LU1037948897.HKD","LU1585245621.USD","LU0130102774.USD","LU2357627491.SGD","LU0006306889.USD","LU0203345920.USD","SG9999001176.USD","IE00BBT3K403.USD","LU0070302665.USD","LU1934455277.USD","LU0265550946.USD","BK4007","LU2361044949.HKD","LU2125909593.SGD","LU1057294990.SGD","LU1093756168.USD","LU0965509283.SGD","LU0211331839.USD","LU1162221912.USD","LU1069347547.HKD","IE00BFTCPJ56.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1974910355.USD","BK4585","LU1983299246.USD","LU1093756325.SGD","LU1116320737.USD","LU0208291251.USD","JDOC","LU2360032135.SGD","LU1430594728.SGD","LU0234572021.USD","SG9999001176.SGD","BK4533","LU1923622614.USD","HRTS","BK4588","IE00BJJMRZ35.SGD","LU0861579265.USD","LU1032466523.USD","LU1035773651.USD","FHLC","IE0002141913.USD","LU0122379950.USD","MRK","LU2089984988.USD","LU0124676726.USD","LU2023250843.SGD","SG9999014575.USD","LU1989772840.SGD","LU2433249047.HKD","TRUH","LU2023250504.SGD","LU1066053197.SGD","LU1061106388.HKD","LU2461242641.AUD","LU2106854487.HKD","PAWZ","SG9999014559.SGD","LU2491049909.HKD","SG9999015341.SGD","LU0265550359.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","BK4559","LU0942090050.USD","IE00B4R5TH58.HKD","LU0098860793.USD","LU2468319806.SGD","FTXH","LU0648001328.SGD","SG9999013999.USD","LU2361044865.SGD","LU0320765489.SGD","LU0823416689.USD","LU1066051811.HKD","LU1934455194.USD","XLV","SG9999014542.SGD","LU1571399168.USD","SG9999015358.SGD","IE00BN8TJ469.HKD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882342","title":"吉倫泰研製的靶向整合素αvβ3治療核藥獲得國家藥監局臨床試驗批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882342?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:52","pubTimestamp":1788227549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","MDTX","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664008470","title":"美國醫療保險和醫療補助服務中心：將為阿肯色州農村醫院提供資金，用於升級救護車、拓展遠程醫療服務並安裝應急發電機","url":"https://stock-news.laohu8.com/highlight/detail?id=2664008470","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664008470?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 02:18","pubTimestamp":1788200331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEIH","LU0266013472.USD","LU1093756325.SGD","UN","LU0390134368.USD","BK4588","HEAL","GDOC","LU1983260115.SGD","IEHS","FDHT","SG9999014021.USD","LGHT","BK4154","IHF","BK4566","LU0070302665.USD","BMED","LU0256863811.USD","HTEC","BK4585","LU0417517546.SGD","UNHW","FXH","LU0211331839.USD","UNHU","LU0170899867.USD","EKG","LU1093756168.USD","HUM","BK4533","LU0320765489.SGD","LU0238689110.USD","LU0348723411.USD","SG9999014005.SGD","UNHG","SG9999014013.SGD","RSPH","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}